Applied Tissue Technologies

Executive Summary

Applied Tissue Technologies (ATT) is a privately held medical device company specializing in advanced wound care and regenerative medicine. Its flagship product, the Platform Wound Device (PWD), is a polyurethane wound chamber designed for negative pressure wound therapy (NPWT) and topical therapeutic delivery without requiring traditional foam or gauze, potentially simplifying treatment and reducing costs. Additionally, ATT commercializes the Xpansion Micro-Autografting kit, an outpatient skin grafting system that enables rapid wound closure with minimal donor site morbidity. Founded in 2008 and headquartered in Marlborough, MA, ATT targets the large and growing chronic wound market, which includes diabetic ulcers, pressure sores, and surgical wounds. The company's technologies offer distinct advantages over conventional therapies, including ease of use, reduced procedure time, and improved patient outcomes. With an aging population and rising diabetes prevalence, ATT is well-positioned to capture market share. However, as a private company, financial details and clinical data are limited. The company's success will depend on gaining regulatory clearances, building clinical evidence, and securing commercial partnerships. Overall, ATT presents an attractive opportunity in the wound care space, though with typical early-stage risks.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Platform Wound Device in Diabetic Ulcers80% success
• Q2 2026Publication of Clinical Results for Xpansion Micro-Autografting Kit85% success
• Q4 2026Strategic Partnership or Distribution Agreement for U.S. Market Expansion65% success